NASPCC Webinar Series Presents:
“Incontinence and Sexual Side Effects of Prostate Cancer Treatment”
With William Brant, MD, FACS, FECSM, Urologist & Men’s Sexual Health Physician in Salt Lake City, Utah
Tuesday, December 8, 2020 at 7:00 pm – 8:00 pm Eastern.
About the Presenter
Dr. Willam Brant attended Dartmouth College and the University of Washington, and obtained his MD at the University of California, San Diego. He completed residencies in Surgery and Urology at the University of Colorado Health Sciences Center and a fellowship in sexual medicine and surgery at UCSF. Dr. Brant’s practice is dedicated to Men’s Health, with a particular focus on sexual and erectile medicine; male urinary incontinence; penile reconstructive surgery; and prosthetic surgery. His current practice is divided between Summit Urology/Granger Medical Clinic and the Salt Lake City Veterans Affairs Medical Center.
Dr. Brant is a member of the AUA, the Sexual Medicine Society, and the Society of Urologic Prosthetic Surgeons, among others. He has authored over 100 works, including various chapters in 6 textbooks in Urology.
“Theranostics in Prostate Cancer*”
With Dr. Michael Morris, Section Head of Prostate Cancer, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center in New York
Monday, January 11, 2021 from 7:00 pm – 8:00 pm Eastern.
* Theranostics describes the combination of using one radioactive drug to diagnose and a second radioactive drug to deliver therapy to treat the main tumor and any metastases
About the Presenter
Dr. Michael Morris is a prostate cancer specialist, clinical investigator, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York, and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan- Kettering Cancer Center, where he was the Chief Fellow as well.
Dr. Morris has led numerous clinical trials, but he has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on radio immunotherapy and other radio-conjugates, bone directed therapy, and other targeted therapies. In the field of diagnostics, he has a keen research interest in developing novel imaging technologies for metastatic prostate cancer and in developing novel imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and novel prostate-specific imaging technologies such as FDHT PET and PSMA-directed PET imaging.
In addition, he is the Medical Director of the Department of Prostate Cancer Clinical Consortium and chairs the GU Committee of the Alliance for Oncology Trials in Oncology (formerly CALGB).
Please also check out our Archived Webinars...